文献速递神经肿瘤

地西他滨增加新抗原和癌睾丸抗原表达以增强T细胞对胶质母细胞瘤的毒性

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma.
PubMed 文献 · Neuro Oncol · 2022-01-01

研究在U87MG和患者来源细胞系中,地西他滨(DAC)通过DNA低甲基化增加新抗原和癌睾丸抗原mRNA表达,促进MHC I类分子呈递,增强抗原特异性T细胞活化和杀伤;患者肿瘤和血液中存在内源性肿瘤特异性T细胞,DAC处理细胞可增强其活化。

要点

  • DAC通过DNA低甲基化上调胶质母细胞瘤细胞新抗原和癌睾丸抗原mRNA表达。
  • DAC增加MHC I类分子呈递新抗原,增强抗原特异性T细胞活化和杀伤。
  • 患者肿瘤和血液中存在内源性肿瘤特异性T细胞,DAC处理细胞可增强其活化。

核心结论

  • DAC在体外增加胶质母细胞瘤免疫原性及其对T细胞反应的易感性,结果支持DAC作为免疫治疗增敏剂的潜在用途。

研究设计与样本

  • U87MG和患者来源细胞系经5-aza-2'-脱氧胞苷(DAC)处理,进行全外显子组和转录组测序,并用新抗原和癌睾丸抗原特异性T细胞进行细胞学实验。

主要发现

  • DAC通过DNA低甲基化增加新抗原和癌睾丸抗原mRNA表达。
  • DAC处理增加肿瘤细胞MHC I类分子对新抗原的呈递,导致新抗原和癌睾丸抗原特异性T细胞活化和对DAC处理癌细胞的杀伤增加。
  • 患者肿瘤和血液中存在内源性癌症特异性T细胞,在DAC处理细胞存在时显示肿瘤特异性活化增加。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出结果支持DAC作为免疫治疗增敏剂的潜在用途,且研究为体外实验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Despite maximal treatment, median survival remains dismal at 14-24 months. Immunotherapies, such as checkpoint inhibition, have revolutionized management of some cancers but have little benefit for GBM patients. This is, in part, due to the low mutational and neoantigen burden in this immunogenically "cold" tumor. METHODS: U87MG and patient-derived cell lines were treated with 5-aza-2'-deoxycytidine (DAC) and underwent whole-exome and transcriptome sequencing. Cell lines were then subjected to cellular assays with neoantigen and cancer testis antigen (CTA) specific T cells. RESULTS: We demonstrate that DAC increases neoantigen and CTA mRNA expression through DNA hypomethylation. This results in increased neoantigen presentation by MHC class I in tumor cells, leading to increased neoantigen- and CTA-specific T-cell activation and killing of DAC-treated cancer cells. In addition, we show that patients have endogenous cancer-specific T cells in both tumor and blood, which show increased tumor-specific activation in the presence of DAC-treated cells. CONCLUSIONS: Our work shows that DAC increases GBM immunogenicity and consequent susceptibility to T-cell responses in vitro. Our results support a potential use of DAC as a sensitizing agent for immunotherapy.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ma R, Rei M, Woodhouse I, et al. Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma. Neuro Oncol. 2022. PMID: 35468205. doi:10.1093/neuonc/noac107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。